Abstract | BACKGROUND: The optimal sequencing of the multiple active agents now available for metastatic castration-resistant prostate cancer (mCRPC) is unclear. Prior reports have suggested diminished responses to sequential lines of androgen receptor (AR)-targeted therapies, but it is unknown whether subsequent taxane-based chemotherapy may be more effective than sequential AR-targeting treatment. We sought to evaluate the clinical activity of enzalutamide versus docetaxel in men with mCRPC who progressed on abiraterone. METHODS: We performed a single-institution retrospective analysis of consecutive mCRPC patients who had progressed on abiraterone therapy and subsequently received either enzalutamide ( n=30) or docetaxel (n=31). We evaluated clinical outcomes including prostate-specific antigen decline of >30% (PSA30) or >50% (PSA50), PSA-progression-free survival (PSA-PFS), and clinical/radiographic PFS. We performed multivariable modeling to control for baseline and on-treatment differences between groups. RESULTS: Compared to subjects who received enzalutamide post- abiraterone, subjects who received docetaxel post- abiraterone had more bone metastases, more visceral metastases, higher baseline PSA, and had more frequent PSA tests while on-treatment. There were no significant differences in PSA30 (41% for enzalutamide vs. 53% for docetaxel) or PSA50 (34% vs. 40%) response rates between the two groups; there remained no difference after stratifying by presence/absence of prior response to abiraterone. Median PSA-PFS was 4.1 versus 4.1 months for the enzalutamide and docetaxel cohorts, respectively (HR 1.35, 95% CI, 0.53-3.66, P=0.502). Median PFS was 4.7 versus 4.4 months, respectively (HR 1.44, 95% CI, 0.77-2.71, P=0.257). PSA-PFS and PFS did not differ after stratifying by prior response to abiraterone. In multivariable analyses, there were no significant differences in PSA-PFS or PFS between the two groups. CONCLUSIONS: Treatment with either enzalutamide or docetaxel produced modest PSA responses and PFS intervals in this abiraterone-pretreated mCRPC population. In this retrospective study with small sample size, no significant differences in outcomes were observed between groups. Therefore, either enzalutamide or docetaxel may be a reasonable option in men who have progressed on abiraterone.
|
Authors | Daniel L Suzman, Brandon Luber, Michael T Schweizer, Rosa Nadal, Emmanuel S Antonarakis |
Journal | The Prostate
(Prostate)
Vol. 74
Issue 13
Pg. 1278-85
(Sep 2014)
ISSN: 1097-0045 [Electronic] United States |
PMID | 25053178
(Publication Type: Comparative Study, Journal Article)
|
Copyright | © 2014 Wiley Periodicals, Inc. |
Chemical References |
- Androstenes
- Androstenols
- Antineoplastic Agents
- Benzamides
- Nitriles
- Taxoids
- Docetaxel
- Phenylthiohydantoin
- enzalutamide
- abiraterone
|
Topics |
- Adenocarcinoma
(drug therapy, secondary)
- Aged
- Androstenes
- Androstenols
(therapeutic use)
- Antineoplastic Agents
(therapeutic use)
- Benzamides
- Bone Neoplasms
(drug therapy, secondary)
- Disease Progression
- Docetaxel
- Drug Resistance, Neoplasm
- Humans
- Male
- Middle Aged
- Nitriles
- Phenylthiohydantoin
(analogs & derivatives, therapeutic use)
- Prostatic Neoplasms, Castration-Resistant
(drug therapy)
- Retrospective Studies
- Taxoids
(therapeutic use)
- Treatment Outcome
|